Research programme: telomerase inhibitors - Geron Corporation
Latest Information Update: 30 Jun 2023
At a glance
- Originator Geron Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 22 Jun 2023 Research programme: telomerase inhibitors - Geron Corporation is available for licensing as of 22 Jun 2023. https://www.geron.com/research-and-development/
- 20 Jun 2023 Early research in Haematological malignancies in USA (unspecified route), prior to June 2023 (Geron pipeline, June 2023)
- 09 Sep 2004 Geron Corporation has patents pending for telomerase inhibitors in worldwide